
    
      This is a multicenter, randomized, open-label, Phase III trial. Eligible participants will be
      randomized in a 1:1 ratio to receive pemetrexed and carboplatin followed by pemetrexed or
      paclitaxel, carboplatin, and bevacizumab followed by bevacizumab as their study treatment.
      Participants randomized to Pemetrexed + Carboplatin + Pemetrexed will receive folic acid,
      vitamin B12, and dexamethasone as stated in the pemetrexed label. Before administration of
      paclitaxel, participants randomized to Paclitaxel + Carboplatin + Bevacizumab will receive
      premedication (dexamethasone, diphenhydramine, and cimetidine or ranitidine) as recommended
      in the paclitaxel label.
    
  